Clinical Focus ›› 2022, Vol. 37 ›› Issue (1): 81-86.doi: 10.3969/j.issn.1004-583X.2022.01.016
Previous Articles Next Articles
-
Received:2021-04-22Online:2022-01-20Published:2022-01-20
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.01.016
| [1] |
Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands[J]. Neuromuscul Disord, 2004, 14(5):337-345.
doi: 10.1016/j.nmd.2004.02.006 URL |
| [2] |
Selva-O'callaghan A, Pinal-Fernandez I, Trallero-Araguás E, et al. Classification and management of adult inflammatory myopathies[J]. Lancet Neurol, 2018, 17(9):816-828.
doi: S1474-4422(18)30254-0 pmid: 30129477 |
| [3] |
Aussy A, Boyer O, Cordel N. Dermatomyositis and immune-mediated necrotizing myopathies: A window on autoimmunity and cancer[J]. Front Immunol, 2017, 8:992.
doi: 10.3389/fimmu.2017.00992 URL |
| [4] |
Furst DE, Amato AA, Iorga ŞR, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan[J]. Muscle Nerve, 2012, 45(5):676-683.
doi: 10.1002/mus.23302 URL |
| [5] | 薛珂, 郑捷, 曹华. 皮肌炎皮肤损害的研究进展[J]. 中国皮肤性病学杂志, 2019, 33(1):92-95. |
| [6] |
Sontheimer RD. Dermatomyositis: An overview of recent progress with emphasis on dermatologic aspects[J]. Dermatol Clin, 2002, 20(3):387-408.
pmid: 12170874 |
| [7] |
Bendewald MJ, Wetter DA, Li X, et al. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: A population-based study in Olmsted County, Minnesota[J]. Arch Dermatol, 2010, 146(1):26-30.
doi: 10.1001/archdermatol.2009.328 pmid: 20083689 |
| [8] |
Lundberg IE, Miller FW, Tjärnlund A, et al. Diagnosis and classification of idiopathic inflammatory myopathies[J]. J Intern Med, 2016, 280(1):39-51.
doi: 10.1111/joim.12524 pmid: 27320359 |
| [9] | 管宇宙. 肌电图规范化检测和临床应用共识修订版[J]. 中华神经科杂志, 2015, 48(11):950-964. |
| [10] |
Cantwell C, Ryan M, O'connell M, et al. A comparison of inflammatory myopathies at whole-body turbo STIR MRI[J]. Clin Radiol, 2005, 60(2):261-267.
pmid: 15664582 |
| [11] | 曲宁. 多发性肌炎/皮肌炎的神经肌肉活检术病理诊断[J]. 中国现代药物应用, 2011, 5(24):44-45. |
| [12] |
Suárez-Calvet X, Gallardo E, Pinal-Fernandez I, et al. RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis[J]. Arthritis Res Ther, 2017, 19(1):174.
doi: 10.1186/s13075-017-1383-0 pmid: 28738907 |
| [13] |
Uruha A, Nishikawa A, Tsuburaya RS, et al. Sarcoplasmic MxA expression: A valuable marker of dermatomyositis[J]. Neurology, 2017, 88(5):493-500.
doi: 10.1212/WNL.0000000000003568 URL |
| [14] |
Betteridge Z, Mchugh N. Myositis-specific autoantibodies: An important tool to support diagnosis of myositis[J]. J Intern Med, 2016, 280(1):8-23.
doi: 10.1111/joim.12451 pmid: 26602539 |
| [15] |
Petri MH, Satoh M, Martin-Marquez BT, et al. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara[J]. Arthritis Res Ther, 2013, 15(2):R48.
doi: 10.1186/ar4207 URL |
| [16] |
Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and meta-analysis[J]. Arthritis Rheum, 2012, 64(2):523-532.
doi: 10.1002/art.v64.2 URL |
| [17] |
Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study[J]. J Am Acad Dermatol, 2011, 65(1):25-34.
doi: 10.1016/j.jaad.2010.09.016 pmid: 21531040 |
| [18] | Labrador-Horrillo M, Martinez MA, Selva-O'callaghan A, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis[J]. J Immunol Res, 2014, 2014:290797. |
| [19] |
Sato S, Kuwana M, Fujita T, et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease[J]. Mod Rheumatol, 2013, 23(3):496-502.
doi: 10.3109/s10165-012-0663-4 URL |
| [20] |
Albayda J, Pinal-Fernandez I, Huang W, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients[J]. Arthritis Care Res (Hoboken), 2017, 69(11):1771-1776.
doi: 10.1002/acr.23188 pmid: 28085235 |
| [21] |
Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts[J]. Sci Rep, 2017, 7(1):188.
doi: 10.1038/s41598-017-00240-6 URL |
| [22] |
Muro Y, Sugiura K, Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients[J]. Autoimmunity, 2013, 46(4):279-284.
doi: 10.3109/08916934.2012.755958 URL |
| [23] |
Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis[J]. Ann Rheum Dis, 2009, 68(10):1621-1625.
doi: 10.1136/ard.2008.097162 pmid: 18930994 |
| [24] |
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7):344-347.
doi: 10.1056/NEJM197502132920706 URL |
| [25] |
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts)[J]. N Engl J Med, 1975, 292(8):403-407.
doi: 10.1056/NEJM197502202920807 URL |
| [26] |
Van Der Meulen MFG, Bronner IM, Hoogendijk JE, et al. Polymyositis: An overdiagnosed entity[J]. Neurology, 2003, 61(3):316-321.
pmid: 12913190 |
| [27] |
Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis[J]. Muscle Nerve, 2015, 51(5):638-656.
doi: 10.1002/mus.24566 pmid: 25641317 |
| [28] | Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis[J]. J Rheumatol, 2002, 29(9):1897-1906. |
| [29] |
Vilela VS, Prieto-González S, Milisenda JC, et al. Polymyositis, a very uncommon isolated disease: Clinical and histological re-evaluation after long-term follow-up[J]. Rheumatol Int, 2015, 35(5):915-920.
doi: 10.1007/s00296-014-3198-5 URL |
| [30] |
Takada T, Hirakata M, Suwa A, et al. Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies[J]. Mod Rheumatol, 2009, 19(2):156-164.
doi: 10.3109/s10165-008-0139-8 URL |
| [31] |
Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity[J]. Ann Rheum Dis, 2017, 76(4):681-687.
doi: 10.1136/annrheumdis-2016-210198 pmid: 27651398 |
| [32] |
Wang Q, Li Y, Ji S, et al. Immunopathological characterization of muscle biopsy samples from immune-mediated necrotizing myopathy patients[J]. Med Sci Monit, 2018, 24:2189-2196.
doi: 10.12659/MSM.907380 URL |
| [33] |
Wang L, Liu L, Hao H, et al. Myopathy with anti-signal recognition particle antibodies: Clinical and histopathological features in Chinese patients[J]. Neuromuscul Disord, 2014, 24(4):335-341.
doi: 10.1016/j.nmd.2014.01.002 URL |
| [34] |
Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016[J]. Neuromuscul Disord, 2018, 28(1):87-99.
doi: 10.1016/j.nmd.2017.09.016 URL |
| [35] |
Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy[J]. J Neurol Neurosurg Psychiatry, 2016, 87(10):1038-1044.
doi: 10.1136/jnnp-2016-313166 pmid: 27147697 |
| [36] |
Rönnelid J, Barbasso Helmers S, Storfors H, et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies[J]. Autoimmun Rev, 2009, 9(1):58-61.
doi: 10.1016/j.autrev.2009.03.005 pmid: 19285154 |
| [37] |
Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: Usefulness of myositis specific antibody[J]. Brain, 2016, 139(Pt 8):2131-2135.
doi: 10.1093/brain/aww054 pmid: 27086869 |
| [38] |
Lefter S, Hardiman O, Ryan AM. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland[J]. Neurology, 2017, 88(3):304-313.
doi: 10.1212/WNL.0000000000003504 pmid: 27927941 |
| [39] |
Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia[J]. Muscle Nerve, 2000, 23(6):970-972.
pmid: 10842277 |
| [40] |
Molberg Ø, Dobloug C. Epidemiology of sporadic inclusion body myositis[J]. Curr Opin Rheumatol, 2016, 28(6):657-660.
doi: 10.1097/BOR.0000000000000327 pmid: 27541181 |
| [41] | Aoki M, Suzuki N. Sporadic inclusion body myositis in Japan[J]. Nihon Rinsho, 2012, 70(5):895-906. |
| [42] |
Li K, Pu C, Huang X, et al. Clinicopathologic features of sporadic inclusion body myositis in China[J]. Neurol Neurochir Pol, 2015, 49(4):245-250.
doi: 10.1016/j.pjnns.2015.06.004 URL |
| [43] |
Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis[J]. Neurology, 2014, 83(5):426-433.
doi: 10.1212/WNL.0000000000000642 URL |
| [44] | de Camargo LV, de Carvalho MS, Shinjo SK, et al. Clinical, histological, and immunohistochemical findings in inclusion body myositis[J]. Biomed Res Int, 2018, 2018:5069042. |
| [45] |
Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis[J]. Muscle nerve, 1998, 21(1):115-117.
pmid: 9427231 |
| [46] |
Lee JH, Boland-Freitas R, Liang C, et al. Neuropathy in sporadic inclusion body myositis: A multi-modality neurophysiological study[J]. Clin Neurophysiol, 2020, 131(11):2766-2776.
doi: 10.1016/j.clinph.2020.07.025 URL |
| [47] |
Güttsches AK, Brady S, Krause K, et al. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis[J]. Ann Neurol, 2017, 81(2):227-239.
doi: 10.1002/ana.24847 URL |
| [48] |
Dalakas MC. Muscle biopsy findings in inflammatory myopathies[J]. Rheum Dis Clin North Am, 2002, 28(4):779-798.
doi: 10.1016/S0889-857X(02)00030-3 URL |
| [49] |
Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis[J]. Ann Neurol, 2013, 73(3):408-418.
doi: 10.1002/ana.v73.3 URL |
| [50] |
Muro Y, Nakanishi H, Katsuno M, et al. Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts[J]. Clin Chim Acta, 2017, 472:1-4.
doi: 10.1016/j.cca.2017.07.002 URL |
| [51] |
Rietveld A, Van Den Hoogen LL, Bizzaro N, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in primary Sjögren's syndrome and systemic lupus erythematosus[J]. Front Immunol, 2018, 9:1200.
doi: 10.3389/fimmu.2018.01200 pmid: 29922285 |
| [52] |
Rigolet A, Musset L, Dubourg O, et al. Inflammatory myopathies with anti-Ku antibodies: A prognosis dependent on associated lung disease[J]. Medicine (Baltimore), 2012, 91(2):95-102.
doi: 10.1097/MD.0b013e31824d9cec URL |
| [53] |
Zamora AC, Hoskote SS, Abascal-Bolado B, et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome[J]. Respir Med, 2016, 118:39-45.
doi: S0954-6111(16)30156-1 pmid: 27578469 |
| [54] |
Cavagna L, Nuño L, Scirè CA, et al. Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: Results from an international retrospective multicenter study[J]. Medicine (Baltimore), 2015, 94(32):e1144.
doi: 10.1097/MD.0000000000001144 URL |
| [55] |
Hervier B, Benveniste O. Clinical heterogeneity and outcomes of antisynthetase syndrome[J]. Curr Rheumatol Rep, 2013, 15(8):349.
doi: 10.1007/s11926-013-0349-8 URL |
| [56] |
Noguchi E, Uruha A, Suzuki S, et al. Skeletal muscle involvement in antisynthetase syndrome[J]. JAMA Neurol, 2017, 74(8):992-999.
doi: 10.1001/jamaneurol.2017.0934 pmid: 28586844 |
| [57] |
Andersson H, Kirkhus E, Garen T, et al. Comparative analyses of muscle MRI and muscular function in anti-synthetase syndrome patients and matched controls: A cross-sectional study[J]. Arthritis Res Ther, 2017, 19(1):17.
doi: 10.1186/s13075-017-1219-y pmid: 28122635 |
| [58] |
Witt LJ, Curran JJ, Strek ME. The Diagnosis and treatment of antisynthetase syndrome[J]. Clin Pulm Med, 2016, 23(5):218-226.
doi: 10.1097/CPM.0000000000000171 URL |
| [59] |
Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients[J]. Ann Rheum Dis, 2014, 73(1):227-232.
doi: 10.1136/annrheumdis-2012-201800 pmid: 23422076 |
| [60] |
Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, et al. A longitudinal cohort study of the anti-synthetase syndrome: Increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies[J]. Rheumatology (Oxford), 2017, 56(6):999-1007.
doi: 10.1093/rheumatology/kex021 pmid: 28339994 |
| [61] |
Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy[J]. Am J Med, 1993, 94(4):379-387.
pmid: 8386437 |
| [62] |
Casal-Dominguez M, Pinal-Fernandez I, Huapaya J, et al. Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome[J]. Clin Exp Rheumatol, 2019, 37(5):858-861.
pmid: 31074729 |
| [63] | Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis[J]. Arch Dermatol, 2006, 142(1):65-69. |
| [64] |
Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease[J]. J Rheumatol, 2013, 40(5):640-646.
doi: 10.3899/jrheum.121043 pmid: 23457378 |
| [65] |
Labirua-Iturburu A, Selva-O'callaghan A, Martínez-Gómez X, et al. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease[J]. Clin Exp Rheumatol, 2013, 31(3):436-439.
pmid: 23465087 |
| [66] |
Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis[J]. Rheumatology (Oxford), 2007, 46(1):124-130.
doi: 10.1093/rheumatology/kel112 URL |
| [67] |
Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis[J]. N Engl J Med, 1993, 329(27):1993-2000.
doi: 10.1056/NEJM199312303292704 URL |
| [68] |
Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis[J]. Arthritis Rheumatol, 2014, 66(3):740-749.
doi: 10.1002/art.v66.3 URL |
| [69] | Iannone F, Scioscia C, Falappone PCF, et al. Use of etanercept in the treatment of dermatomyositis: A case series[J]. J Rheumatol, 2006, 33(9):1802-1804. |
| [70] |
Hengstman GJD, Van Den Hoogen FHJ, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations[J]. Eur Neurol, 2003, 50(1):10-15.
pmid: 12824706 |
| [71] |
Hengstman GJD, Van Den Hoogen FHJ, Van Engelen BGM. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: Long-term follow-up[J]. Eur Neurol, 2004, 52(1):61-63.
pmid: 15240986 |
| [72] |
Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis[J]. Rheumatology (Oxford), 2011, 50(7):1344-1346.
doi: 10.1093/rheumatology/ker152 pmid: 21515628 |
| [73] |
Zong M, Dorph C, Dastmalchi M, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: A mechanistic study with 12 months follow-up[J]. Ann Rheum Dis, 2014, 73(5):913-920.
doi: 10.1136/annrheumdis-2012-202857 pmid: 23625983 |
| [74] |
Ruck T, Bittner S, Kuhlmann T, et al. Long-term efficacy of alemtuzumab in polymyositis[J]. Rheumatology (Oxford), 2015, 54(3):560-562.
doi: 10.1093/rheumatology/keu484 URL |
| [75] |
Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes[J]. Mol Ther, 2017, 25(4):870-879.
doi: S1525-0016(17)30092-8 pmid: 28279643 |
| [76] |
Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis[J]. Neurology, 2006, 66(2 Suppl 1):S123-S124.
doi: 10.1212/01.wnl.0000192258.32408.54 URL |
| [77] | Murata KY, Kouda K, Tajima F, et al. Balloon dilation in sporadic inclusion body myositis patients with dysphagia[J]. Clin Med Insights Case Rep, 2013, 6:1-7. |
| [78] |
Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis[J]. Curr Rheumatol Rep, 2012, 14(3):244-251.
doi: 10.1007/s11926-012-0248-4 pmid: 22467380 |
| [1] | Liu Xiangdong, Cai Yandong, Qin Yanjun, Li Yunsong, Li Liang, Gao Ruijiao, Ren Lei, Zhang Yanrong. Exertional rhabdomyolysis complicated with acute renal insufficiency and catheter-related thrombosis: One case and literature review [J]. Clinical Focus, 2022, 37(9): 831-833. |
| [2] | Lu Haitang. Clinical features of statin-induced myopathy [J]. Clinical Focus, 2015, 30(12): 1378-1.38114e+007. |
| [3] | . [J]. CLINICAL FOCUS, 2013, 28(8): 886-0. |
| [4] | . [J]. Clinical Focus, 2012, 27(18): 1596-0. |
| [5] | . [J]. Clinical Focus, 2012, 27(17): 1533-0. |
| [6] | . [J]. Clinical Focus, 2012, 27(17): 0-0. |
| [7] | . [J]. CLINICAL FOCUS, 2010, 25(1): 65-0. |
| [8] | . [J]. CLINICAL FOCUS, 2009, 24(7): 589-589. |
| [9] | . [J]. CLINICAL FOCUS, 2009, 24(1): 32-0. |
| [10] | . [J]. CLINICAL FOCUS, 2006, 21(18): 1345-1345. |
| [11] | . [J]. CLINICAL FOCUS, 2005, 20(23): 1378-1379. |
| [12] | . [J]. CLINICAL FOCUS, 2004, 19(5): 285-286. |
| [13] | . [J]. CLINICAL FOCUS, 2003, 18(18): 1079-1080. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||